Exploring SGLT2 Inhibitor Benefits in Chronic Kidney Disease
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.
1:21 Treatment landscape for CKD
3:42 Prevalence of CKD in people with diabetes
5:25 Mechanism of SGLT2 inhibitors
8:05 Benefits of SGLT2 inhibitors in non-diabetic patients
9:02 Cardiovascular benefits of SGLT2 inhibitors
11:24 Comparative efficacy of SGLT1,2 inhibitors
13:54 Impact of SGLT2 inhibitors on diabetes
16:50 Adverse effects of SGLT2 inhibitors
20:30 Effect of SGLT2 inhibitors in euglycemic DKA
23:08 Combining SGLT2 inhibitors with other diabetes medications
28:14 Combining finerenone with SGLT2 inhibitors
